Cargando…

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer

Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monie, Archana, Hung, Chien-Fu, Roden, Richard, Wu, T-C
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727782/ https://www.ncbi.nlm.nih.gov/pubmed/19707432

Ejemplares similares

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
por: Kumakech, Edward, et al.
Publicado: (2016)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
por: Chuang, Chi-Mu, et al.
Publicado: (2010)

Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
por: Chuang, Chi-Mu, et al.
Publicado: (2009)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom
por: Van Effelterre, Thierry P, et al.
Publicado: (2015)

Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
por: Wu, Chao-Yi, et al.
Publicado: (2010)

Efficient Delivery of DNA Vaccines using Human Papillomavirus Pseudovirions
por: Peng, Shiwen, et al.
Publicado: (2010)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
por: Peng, Shiwen, et al.
Publicado: (2021)

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand
por: Jiamsiri, Suchada, et al.
Publicado: (2022)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali
por: Téguété, Ibrahima, et al.
Publicado: (2017)

Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis
por: Haghshenas, Mohammad Reza, et al.
Publicado: (2017)

Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer
por: Peng, Shiwen, et al.
Publicado: (2015)

Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
por: Chua, Brandon Wen Bing, et al.
Publicado: (2022)

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
por: Diaz, M, et al.
Publicado: (2008)

Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
por: Vu, Lan TH, et al.
Publicado: (2013)

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells
por: Peng, Shiwen, et al.
Publicado: (2014)

Ovarian Cancer Gene Therapy Using HPV-16 Pseudovirion Carrying the HSV-tk Gene
por: Hung, Chien-Fu, et al.
Publicado: (2012)

Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
por: Peng, Shiwen, et al.
Publicado: (2023)

Cross-neutralizing antibodies elicited by the Cervarix(®) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities()
por: Bissett, Sara L., et al.
Publicado: (2014)

Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program
por: Matsumoto, Koji, et al.
Publicado: (2019)

HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile
por: Lagos, Marcela, et al.
Publicado: (2015)

The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia
por: Mu, Lin, et al.
Publicado: (2020)

Cervical intraepithelial neoplasia 3, coinfected with HPV-16 and -18--case report.
por: Park, J. S., et al.
Publicado: (1993)

High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine
por: Hooi, Desiree J, et al.
Publicado: (2018)

Does HPV vaccination prevent cervical cancer?
por: Miller, Anthony B.
Publicado: (2013)

Comment on “Will HPV vaccination prevent cervical cancer”
por: Zhang, Shaokai, et al.
Publicado: (2020)

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix(®) and Gardasil(®) Human Papillomavirus Vaccines in 12-15 Year Old Girls
por: Draper, Eve, et al.
Publicado: (2013)

Cervical and Oral Screening for HR-HPV types 16 and 18 among Sudanese Women Cervical Lesions
por: Elasbali, Abdelbaset Mohamed, et al.
Publicado: (2012)

The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study
por: Kurokawa, Tetsuji, et al.
Publicado: (2020)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice
por: Peng, Shiwen, et al.
Publicado: (2022)

Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program
por: Onuki, Mamiko, et al.
Publicado: (2022)

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination
por: Yang, Benjamin, et al.
Publicado: (2015)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
por: Bhuyan, Prakash K., et al.
Publicado: (2020)

Opportunities to improve immune-based prevention of HPV-associated cancers
por: Stern, Peter L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qeh2cu47vr2e09u3v89mjbir8t